This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

I. Results of a Prospective, Placebo-Controlled Comparison of Alprazolam and Imipramine

Edward Schweizer, MD; Karl Rickels, MD; Susan Weiss, RN, MEd; Steven Zavodnick, MD

Arch Gen Psychiatry. 1993;50(1):51-60.

Abstract
• One hundred six patients diagnosed according to DSM-III as suffering from agoraphobia with panic disorder, panic disorder with limited phobic avoidance, or uncomplicated panic disorder entered an acute 8-week treatment phase. Patients who improved received an additional 6 months' maintenance treatment. Significantly more patients treated with alprazolam than with imipramine hydrochloride or placebo remained in therapy and experienced panic attack and phobia relief during the acute treatment phase. During the maintenance phase, neither tolerance nor daily dose increase was observed. All patients who completed the maintenance phase (27 in the alprozolam group, 11 in the imipramine group, and 10 in the placebo group) were panic free at the end of 8 months of study treatment. Alprazolam therapy was effective and well tolerated at a mean daily dose of 5.7 mg. Imipramine hydrochloride (175 mg/d) also produced significant panic relief but was associated with poor patient acceptance.

Author Affiliations
From the Psychopharmacology Research Unit, Department of Psychiatry, University of Pennsylvania, Philadelphia (Drs Rickels and Schweizer and Ms Weiss); and the Department of Psychiatry, Pennsylvania Hospital, Philadelphia (Dr Zavodnick).

Footnotes
Accepted for publication June 18, 1992.

Reprint requests to University Science Center, Suite 803, 3600 Market St, Philadelphia, PA 19104 (Dr Rickels).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Strategies for discontinuing long-term benzodiazepine use: Meta-analysis
Voshaar et al.
Br. J. Psychiatry 2006;189:213-220.
ABSTRACT | FULL TEXT  

Sertraline in the Treatment of Panic Disorder: A Double-Blind Multicenter Trial
Pohl et al.
Am. J. Psychiatry 1998;155:1189-1195.
ABSTRACT | FULL TEXT  

Psychopharmacological Treatment of Panic Disorder
Sundel and Sundel
Research on Social Work Practice 1998;8:426-451.
ABSTRACT  

Antidepressant Prescribing Practices of Outpatient Psychiatrists
Olfson et al.
Arch Gen Psychiatry 1998;55:310-316.
ABSTRACT | FULL TEXT  

The effectiveness of cognitive-behavior therapy for panic disorder without concurrent medication treatment: a reply to Power and Sharp
Otto et al.
J Psychopharmacol 1996;10:254-256.
 

Psychiatry
Freedman and Stahl
JAMA 1993;270:252-254.
ABSTRACT  

Maintenance Drug Treatment for Panic Disorder: II. Short- and Long-term Outcome After Drug Taper
Rickels et al.
Arch Gen Psychiatry 1993;50:61-68.
ABSTRACT